Abcellera Biologics Inc (ABCL)vsRegeneron Pharmaceuticals Inc (REGN)
ABCL
Abcellera Biologics Inc
$5.24
+8.71%
HEALTHCARE · Cap: $1.54B
REGN
Regeneron Pharmaceuticals Inc
$714.89
+0.82%
HEALTHCARE · Cap: $74.34B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 19759% more annual revenue ($14.92B vs $75.13M). REGN leads profitability with a 29.6% profit margin vs -194.9%. REGN earns a higher WallStSmart Score of 64/100 (C+).
ABCL
Hold41
out of 100
Grade: D
REGN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+64.8%
Fair Value
$8.88
Current Price
$5.24
$3.64 discount
Margin of Safety
+50.8%
Fair Value
$1452.32
Current Price
$714.89
$737.43 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 788.0% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Earnings expanding 45.9% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 30 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 20.7%
Areas to Watch
Smaller company, higher risk/reward
ROE of -14.5% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
Weak financial health signals
Earnings declined 7.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABCL
The strongest argument for ABCL centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 788.0% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Altman Z-Score, Market Cap, Profit Margin. Profitability is solid with margins at 29.6% and operating margin at 20.7%. Revenue growth of 19.0% demonstrates continued momentum.
Bear Case : ABCL
The primary concerns for ABCL are Market Cap, Return on Equity, Free Cash Flow.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
ABCL profiles as a hypergrowth stock while REGN is a growth play — different risk/reward profiles.
ABCL carries more volatility with a beta of 1.03 — expect wider price swings.
ABCL is growing revenue faster at 788.0% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (64/100 vs 41/100), backed by strong 29.6% margins and 19.0% revenue growth. ABCL offers better value entry with a 64.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abcellera Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
Visit Website →Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?